RadioMedix, Inc. is a clinical-stage biotechnology company focused on discovery and manufacturing of innovative radiopharmaceuticals.
RadioMedix is a fully integrated clinical-stage radiopharmaceutical company operating a full drug discovery engine, and a state-of-the art 27,500 sq ft cGMP manufacturing facility complete with QA/QC capabilities. RadioMedix has a proven track record of success in developing and commercializing diagnostic and therapeutic agents for various solid tumor indications, with a specific focus on targeted alpha therapies. RadioMedix pioneered the developed Cu-64 DOTATATE,(Detectnet™ ) which was licensed to Curium, in addition to Ac-225 PSMAI&T (AcPSMA), now licensed to Fusion Pharmaceuticals, an AstraZeneca company. RadioMedix lead clinical asset— Pb-212-DOTAMTATE (AlphaMedix™ developed in collaboration with OranoMed), for the treatment of SSTR2+ NETs, was licensed in September of 2024 to Sanofi for further development and is forecasted to be the world’s first approved alpha-based precision oncology treatment.
RadioMedix continues to be a leader in developing innovative precision oncology radiotherapeutics with ongoing programs for the treatment of glioblastoma, pancreatic duct adenocarcinoma, and liver and urological cancers. RadioMedix is at the forefront of democratizing access to the Pb-212 with the advance of a proprietary 212Pb generator, developed with the end user in mind delivering high purity and yield without the need of a hotcell. In late-stage development, with a projected launch in 2026 is AMINOT, our PRRT enabling kidney protective agent. Upon approval, AMINOT will be the first cGMP compliant kidney protective agent available on the market. Since it’s inception in
Brands: AlphaMedix, Detectnet